Beta-Thalassemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Beta-Thalassemia Market Outlook
Thelansis’s “Beta-Thalassemia Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Beta-Thalassemia treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Beta-Thalassemia Overview
Beta-thalassemia
(BT) is a genetic disorder characterized by a deficiency (Beta+) or absence
(Beta0) of the beta-globin chains of hemoglobin (Hb). There are three main
types of BT: BT-minor, BT-major, and BT-intermedia. BT-minor is the
heterozygous form and is generally asymptomatic. At the same time, BT-major is
the homozygous form that causes splenomegaly, microcytic, and hypochromic
anemia and requires systematic transfusions to maintain Hb levels above 90-100
g/L. Long-term transfusion results in iron overload, which can cause
significant morbidity and hamper the vital prognosis. BT-intermedia is less
severe than BT-major and diagnosed later in life, and patients may or may not
require occasional transfusions. Diagnosis of BT relies on analyzing Hb by electrophoresis
or HPLC. Treatment options for BT include a combination of regular transfusions
and iron chelation therapy, which has led to increased survival during the last
40 years. The prognosis depends on the severity of the condition, mainly if appropriate
treatment is provided.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment